Fortress Biotech (FBIO) 10-K2020 FY Annual report

Filed: 31 Mar 21, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abundance, accessibility, Accutane, Aid, antisense, Antitrust, ascertainment, aspect, ATMP, attended, autoimmune, Biden, black, bona, bowel, box, bulk, Calimmune, carryback, Cassiopea, castration, Chancellor, combat, Commissioner, compelled, complementary, computerized, conditionally, contest, contractor, convened, coupled, CRL, CRPC, culpability, Cushman, cybersecurity, DAK, Dawson, deletion, Democratic, dismissed, displace, distancing, DNA, domestic, driven, dysregulated, Eastern, economy, effector, Elijah, encumbered, enjoined, enterprise, entertainment, ependymoma, EPI, episode, ESMO, Euro, evolved, Exhibit, exon, expert, FBIOP, fell, fide, Foundation, Galderma, GMP, Hazard, helix, highest, Hoenlein, home, HSR, immaterial, indiciation, Inline, insert, insulin, inter, invade, irritable, isotretinoin, iterative, Janet, Jersey, Joe, KS, language, LentiBOOST, LentiBOOSTTM, Leo, live, liver, longest, Lymphodepleting, lymphodepletion, magnetic, Malcolm, male, mCRPC, mCSCC, MDL, medulloblastoma, milstone, missed, MMA, mRNA, multicohort, mutant, NaN, native, neurotoxicity, newborn, nodular, nonclinical, Oaktree, official, oHSV, ompany, Oncugenuity, organizational, outbreak, outsized, overseen, Oxford, pandemic, parallel, Paycheck, payoff, payroll, pendency, peptic, PNA, PNH, postmarket, PPS, precautionary, pregnant, proximity, PSA, psychiatric, purported, quarantine, randomized, reborrowed, recalcitrant, rededication, reexamination, refundable, reimport, reintroduce, remote, remotely, reorganization, Republican, rescindment, resonance, resubmission, resume, retinoid, Retreat, Samsung, satisfactorily, score, screening, Secretary, Sentynl, serum, SIRION, skill, social, soft, SPA, Steering, sterilization, strand, stream, substance, Sun, takeover, temporarily, thereunder, tied, timeframe, timeline, tomography, Transduced, triangular, Truncated, UAB, unaware, unconditionally, undergone, untitled, untreated, unviable, upstream, Verrica, version, virtual, volumetric, voluntarily, Vyne, waiting, Warp, Woodcock, workplace, worsen, Wuhan

Removed: abnormality, analgesic, answer, appealed, assume, assuming, attestation, automatic, awarding, BDO, centrally, Cephalon, clarify, computation, conform, contact, continual, Crohn, cycle, DEF, deny, denying, deteriorate, disagree, discontinue, encountered, Escala, EUR, Falk, FDIC, forfeiture, formula, Frankfurt, fulfilled, Germany, goodwill, hacker, herewith, hypothetical, implied, indexed, inInternal, inresearch, instituteinter, instructing, intent, internally, introducing, IPO, largest, mAb, matured, membership, mg, Mine, NCI, nil, notification, operated, opioid, outsourced, PARP, peer, possessing, procedural, prodrug, qualitative, recoverability, recovered, requesting, reset, select, simple, software, standpoint, subsystem, Supplementary, synthetic, systemic, terrorist, Teva, theEunice, thereon, underperformance, undistributed, unqualified, Unresolved, USA, vandalism, verifiable, viewed, voted, waive, war, weighting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

FBIO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Fortress Biotech, Inc. (the “Company”) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

_
Dated: March 31, 2021	By:	/s/ Lindsay A. Rosenwald, M.D.
		Lindsay A. Rosenwald, M.D.
		Chairman, President and Chief Executive Officer
		(Principal Executive Officer)